HAEM5:Follicular dendritic cell sarcoma - Revision history

Bailey.Glen at 17:15, 3 July 2025

2025-07-03T17:15:22Z

← Older revision		Revision as of 12:15, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:35, 25 May 2025

2025-05-25T21:35:36Z

← Older revision		Revision as of 16:35, 25 May 2025
Line 145:		Line 145:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 202:		Line 202:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 246:		Line 246:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:11, 25 May 2025

2025-05-25T20:11:10Z

← Older revision		Revision as of 15:11, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|Follicular dendritic cell tumour
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:36, 24 March 2025

2025-03-24T17:36:47Z

← Older revision		Revision as of 12:36, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Follicular dendritic cell sarcoma}}		{{DISPLAYTITLE:Follicular dendritic cell sarcoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG		Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T22:25:07Z

Removed old template contents

Show changes

Bailey.Glen at 18:46, 10 February 2025

2025-02-10T18:46:19Z

Show changes

Bailey.Glen at 18:18, 10 February 2025

2025-02-10T18:18:15Z

← Older revision		Revision as of 13:18, 10 February 2025
Line 99:		Line 99:


	<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":0" /><ref name=":2" /></blockquote>		<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":0" /><ref name=":2" /><blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			</blockquote>
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==

Line 123:		Line 126:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	The following rearrangements have been reported in individual cases, but whether they are recurrent is not yet known.		The following rearrangements have been reported in individual cases, but whether they are recurrent is not yet known.
Line 136:		Line 139:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 206:		Line 212:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Although no recurrent chromosomal alterations have been identified in FDCS, the tumors often show complex karyotypes with loss of whole or partial chromosomes being the most frequent aberration. Losses frequently occur in regions harboring important tumor suppressor genes.<ref name=":2" />		Although no recurrent chromosomal alterations have been identified in FDCS, the tumors often show complex karyotypes with loss of whole or partial chromosomes being the most frequent aberration. Losses frequently occur in regions harboring important tumor suppressor genes.<ref name=":2" />

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 245:		Line 254:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	Put your text here and/or fill in the tables		Put your text here and/or fill in the tables
Line 370:		Line 379:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 395:		Line 407:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	FDCS primarily shows alterations in the NF-κB signaling pathway. Unlike the dendritic cell and histiocytic neoplasms of hematopoietic origin, aberrations in the MAPK pathway are uncommon.		FDCS primarily shows alterations in the NF-κB signaling pathway. Unlike the dendritic cell and histiocytic neoplasms of hematopoietic origin, aberrations in the MAPK pathway are uncommon.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:39, 6 September 2024

2024-09-06T22:39:46Z

← Older revision		Revision as of 17:39, 6 September 2024
Line 15:		Line 15:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	~~[[HAEM4:Histiocytic and Dendritic Cell Neoplasms]] (WHO 4th ed.)<ref name~~=":0"~~>Chan JKC, et al~~.~~, (2017~~). Follicular dendritic cell sarcoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-~~171.</ref>~~		{\| class="wikitable"
			!Structure
	Stroma-derived neoplasms of lymphoid tissues ~~(WHO 5th ed.)<ref name=":1">{{Cite journal~~\|~~last=Alaggio~~\|~~first=Rita~~\|~~last2=Amador~~\|first2=Catalina\|last3=Anagnostopoulos\|first3=Ioannis\|last4=Attygalle\|first4=Ayoma D.\|last5=Araujo\|first5=Iguaracyra Barreto de Oliveira\|last6=Berti\|first6=Emilio\|last7=Bhagat\|first7=Govind\|last8=Borges\|first8=Anita Maria\|last9=Boyer\|first9=Daniel\|date=2022-07\|~~title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms~~\|~~url=https://pubmed.ncbi.nlm.nih.gov/35732829~~\|~~journal=Leukemia\|volume=36\|issue=7\|pages=1720–1748\|doi=10.1038/s41375~~-~~022-01620-2\|issn=1476-5551~~\|~~pmc=9214472\|pmid=35732829}}</ref>~~		!Disease
			\|-
	~~==Cancer Sub-Classification /~~ Subtype==		\|Book
			\|Haematolymphoid Tumours (5th ed.)
	~~Mesenchymal~~ dendritic cell ~~neoplasms (WHO 5th ed.)<ref name=":1" />~~		\|-
			\|Category
			\|Stroma-derived neoplasms of lymphoid tissues
			\|-
			\|Family
			\|Mesenchymal dendritic cell neoplasms
			\|-
			\|Type
			\|Follicular dendritic cell neoplasms
			\|-
			\|Subtype(s)
			\|Follicular dendritic cell sarcoma
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 21:57, 6 September 2024

2024-09-06T21:57:39Z

Show changes

Bailey.Glen: Undo revision 14868 by Bailey.Glen (talk)

2024-09-04T00:21:53Z

Undo revision 14868 by Bailey.Glen (talk)

Show changes